Need help now? Free crisis lines and helplines, worldwide — chapter 02 →
0 results for

The Microbiome & Chronic Disease

Category 19 of 20 in chapter 17, The Research Behind It, of Notbroken's Free Metabolic & Mental Health Help Directory: 16 listings, each carefully picked (listed, not endorsed). All 280 listings in The Research Behind It · Open the full directory of 2299 listings.
16
Listings
19 / 20
Category
17 / 18
Chapter
Latest Edition Always download the most up-to-date version, free, at notbroken.io
Know someone who could benefit? Share this guide with them.
Free to use · No account needed
Navigation
Contents
17
The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows
THE EVIDENCE
THE EVIDENCE

The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows

Why would a support group, a walking club, a low-carb book or an online CBT course help — and what drives chronic illness in the first place? This chapter gathers the research behind each part of the directory, and the research on causes: metabolic therapies, the nutrients in food, plastics and pollution, stress and trauma, the microbiome, and damp and mould. That is 280 studies, reviews and clinical guidelines, every one free to read and download in full, permanently and without a login. Most are kept in PubMed Central, the US National Library of Medicine's public archive; the rest are open access at the publisher, or free guidance from the World Health Organization and NICE. Each entry says what was found, why it matters here — which listings it backs up, or what it explains about chronic disease — and how strong the evidence is: strong (systematic reviews and guidelines with consistent findings), moderate (smaller or lower-certainty reviews, single large trials and large cohort studies) or early (pilot, cross-sectional and laboratory studies — promising, not proof). Studies that follow people over time show links, not proof of cause, and the entries say so. Where a study was funded by a company, or its authors run a listed programme, the note says so; where a listed book or service was not itself tested, the entry says it backs the approach rather than the product. Research moves on, so read these as good reasons to try something, not guarantees — and talk to your own clinician before changing a treatment or a medicine. Every paper was checked at least twice: by the researcher who chose it and again, independently, against its abstract and full text (the first 186 a third time); its public record was checked for corrections, retractions and expressions of concern (none is retracted), every number was looked up in the full text, and every link was opened in a browser.

The Microbiome & Chronic Disease

Role of the gut microbiota in nutrition and health — Valdes et al., BMJ 2018

Narrative review, including a summary table of 22 systematic reviews of probiotic trials (313 trials, 46,826 participants). Early evidence. BMJ 2018;361:k2179. DOI 10.1136/bmj.k2179. Free full text in PubMed Central (PMC6000740) — open access, CC BY-NC 4.0. Note: Narrative rather than systematic review; much of the evidence it covers is observational or from animals, and authors declare links to nutrition, prebiotic and synbiotic companies.
What It Found
The authors explain how gut microbes ferment fibre into short-chain fatty acids and how diet, medicines and antibiotics shape the microbiome. Lower microbial diversity has been found in obesity, cardiometabolic and autoimmune conditions, but they stress that observational studies cannot show cause. Their summary of 22 systematic reviews (313 trials, 46,826 people) found good evidence that probiotics help prevent some conditions, such as diarrhoea and, in children, eczema.
Why It Matters Here
Explains how food, fibre and medicines shape the gut microbiome and what probiotics can and cannot do; backs up the microbiome-science and probiotic guides in chapter 15 and the home-cooking and food-and-mood resources in chapter 10.
Narrative review, including a summary table of 22 systematic reviews of probiotic trials (313 trials, 46,826 participants). Early evidence. BMJ 2018;361:k2179. DOI 10.1136/bmj.k2179. Free full text in PubMed Central (PMC6000740) — open access, CC BY-NC 4.0. Note: Narrative rather than systematic review; much of the evidence it covers is observational or from animals, and authors declare links to nutrition, prebiotic and synbiotic companies.

Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases — Sanna et al., Nat Genet 2019

Mendelian randomisation study — genotypes, gut metagenomes and stool short-chain fatty acids in 952 Dutch adults without diabetes, tested against 17 metabolic traits; propionate result replicated in UK Biobank. Early evidence. Nat Genet 2019;51(4):600–605. DOI 10.1038/s41588-019-0350-x. Free full text in PubMed Central (PMC6441384). Note: Effects were small and rest on Mendelian randomisation assumptions; the propionate result missed the authors' main significance threshold until replicated in UK Biobank.
What It Found
Most microbiome–disease links are associations. This study used people's genes as a natural experiment (Mendelian randomisation) in 952 adults. Genetically higher gut production of butyrate, made when bacteria ferment fibre, was linked with a better insulin response after a glucose drink (P = 9.8×10⁻⁵), and higher stool propionate with higher type 2 diabetes risk (odds ratio 1.15 per standard deviation; P = 0.004). The authors read this as evidence of a causal effect.
Why It Matters Here
Explains why fibre-fermenting gut bacteria may matter for blood-sugar control, using genetics to test cause rather than simple association; background for the gut-health and metabolic resources elsewhere in the directory rather than support for any one listing.
Mendelian randomisation study — genotypes, gut metagenomes and stool short-chain fatty acids in 952 Dutch adults without diabetes, tested against 17 metabolic traits; propionate result replicated in UK Biobank. Early evidence. Nat Genet 2019;51(4):600–605. DOI 10.1038/s41588-019-0350-x. Free full text in PubMed Central (PMC6441384). Note: Effects were small and rest on Mendelian randomisation assumptions; the propionate result missed the authors' main significance threshold until replicated in UK Biobank.

Gut microbiota–derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis — Li et al., Am J Clin Nutr 2022

Umbrella review and updated meta-analyses of observational studies — 24 meta-analyses, 82 studies, 18 health outcomes. Moderate evidence. Am J Clin Nutr 2022;116(1):230–243. DOI 10.1093/ajcn/nqac074. Free full text in PubMed Central (PMC9257469) — open access, CC BY 4.0. Note: All included studies were observational, so cause cannot be inferred; TMAO is closely tied to kidney function, and a Mendelian randomisation study found no causal link with heart disease.
What It Found
TMAO forms when gut bacteria break down choline and carnitine (found in meat, eggs, dairy and seafood) and the liver converts the product. People with the highest blood TMAO had a higher risk of major cardiovascular events (hazard ratio 1.74, 95% CI 1.55 to 1.95; 36 studies) and of death from any cause (1.60, 1.43 to 1.79; 37 studies) than those with the lowest. Six links, including diabetes and high blood pressure, were rated 'highly suggestive'; none 'convincing'.
Why It Matters Here
Explains one way gut bacteria may connect diet with heart, kidney and metabolic disease; the authors call TMAO a possible risk marker and say it is not yet known whether lowering it would prevent disease.
Umbrella review and updated meta-analyses of observational studies — 24 meta-analyses, 82 studies, 18 health outcomes. Moderate evidence. Am J Clin Nutr 2022;116(1):230–243. DOI 10.1093/ajcn/nqac074. Free full text in PubMed Central (PMC9257469) — open access, CC BY 4.0. Note: All included studies were observational, so cause cannot be inferred; TMAO is closely tied to kidney function, and a Mendelian randomisation study found no causal link with heart disease.

Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression — Sharpton et al., Am J Clin Nutr 2019

Systematic review and meta-analysis — 21 randomised trials, 1,252 people with non-alcoholic fatty liver disease. Moderate evidence. Am J Clin Nutr 2019;110(1):139–149. DOI 10.1093/ajcn/nqz042. Free full text in PubMed Central (PMC6599739). Note: Results varied widely between trials (I² over 90% for ALT and liver stiffness), trials were short, and none used liver biopsy, so long-term benefit is unknown.
What It Found
Twenty-one randomised trials (1,252 people with non-alcoholic fatty liver disease, now called MASLD) tested probiotics or synbiotics (probiotics plus prebiotic fibre) for 8–28 weeks. They lowered the liver enzyme ALT (by 11.2 IU/L; 16 trials) and liver stiffness (by 0.70 kPa; 4 trials), and raised the odds of less fat on ultrasound (odds ratio 2.40, 95% CI 1.50 to 3.84; 6 trials). No trials of antibiotics or faecal transplant were found; none measured liver biopsy changes.
Why It Matters Here
Backs up the probiotic guides in chapter 15 (WGO probiotics guideline, Clinical Guide to Probiotic Products, ISAPP) for people with fatty liver; most relevant to anyone told they have fatty liver disease who is asking about probiotics.
Systematic review and meta-analysis — 21 randomised trials, 1,252 people with non-alcoholic fatty liver disease. Moderate evidence. Am J Clin Nutr 2019;110(1):139–149. DOI 10.1093/ajcn/nqz042. Free full text in PubMed Central (PMC6599739). Note: Results varied widely between trials (I² over 90% for ALT and liver stiffness), trials were short, and none used liver biopsy, so long-term benefit is unknown.

Effects of fecal microbiota transplantation on glycemic and lipid profiles in overweight or obese patients with metabolic disorders: a systematic review and meta-analysis — Zhang et al., Front Endocrinol (Lausanne) 2025

Systematic review and meta-analysis — 11 randomised trials, 320 adults with overweight or obesity and metabolic disease (PROSPERO-registered). Moderate evidence. Front Endocrinol (Lausanne) 2025;16:1737543. DOI 10.3389/fendo.2025.1737543. Free full text in PubMed Central (PMC12745229) — open access, CC BY 4.0. Note: Low-certainty evidence from small trials with different donors and methods; an earlier meta-analysis found small short-term HbA1c and insulin improvements but no weight loss.
What It Found
Eleven randomised trials (320 adults with overweight or obesity plus metabolic syndrome, type 2 diabetes or related problems) tested faecal microbiota transplant (FMT) from healthy lean donors. Pooled, FMT did not significantly change body mass index (−0.65; P = 0.07), insulin resistance (HOMA-IR −0.64; P = 0.06) or HbA1c (P = 0.74), on low-certainty evidence. The authors conclude its true metabolic benefit remains uncertain.
Why It Matters Here
Explains that faecal transplant is not an established treatment for weight or blood sugar; context for the FMT clinic directory in chapter 01 and the regulated FMT services in chapter 15, whose proven use is recurrent C. difficile infection.
Systematic review and meta-analysis — 11 randomised trials, 320 adults with overweight or obesity and metabolic disease (PROSPERO-registered). Moderate evidence. Front Endocrinol (Lausanne) 2025;16:1737543. DOI 10.3389/fendo.2025.1737543. Free full text in PubMed Central (PMC12745229) — open access, CC BY 4.0. Note: Low-certainty evidence from small trials with different donors and methods; an earlier meta-analysis found small short-term HbA1c and insulin improvements but no weight loss.

Fecal transplantation for treatment of inflammatory bowel disease — Imdad et al., Cochrane Database Syst Rev 2023

Cochrane systematic review and meta-analysis — 12 randomised trials, 550 adults and children with ulcerative colitis or Crohn's disease. Moderate evidence. Cochrane Database Syst Rev 2023;(4):CD012774. DOI 10.1002/14651858.CD012774.pub3. Free full text in PubMed Central (PMC10133790). Note: Low-certainty evidence from small, short trials using different donors and routes; no trial tested FMT for bringing Crohn's disease into remission.
What It Found
Twelve randomised trials (550 people) tested faecal microbiota transplant (FMT) for inflammatory bowel disease. In active ulcerative colitis, FMT may increase the chance of clinical remission (10 trials, 468 people; risk ratio 1.79, 95% CI 1.13 to 2.84; low-certainty evidence), with little or no difference in overall side effects. Evidence on serious harms, on keeping remission and on Crohn's disease was very uncertain.
Why It Matters Here
Explains where faecal transplant stands for Crohn's and colitis: it may help bring active ulcerative colitis into remission (low-certainty evidence) but is unproven for Crohn's; context for the FMT listings in chapter 01, the FMT programmes and trial registries in chapter 15 and the IBD groups in chapters 06 and 15.
Cochrane systematic review and meta-analysis — 12 randomised trials, 550 adults and children with ulcerative colitis or Crohn's disease. Moderate evidence. Cochrane Database Syst Rev 2023;(4):CD012774. DOI 10.1002/14651858.CD012774.pub3. Free full text in PubMed Central (PMC10133790). Note: Low-certainty evidence from small, short trials using different donors and routes; no trial tested FMT for bringing Crohn's disease into remission.

Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study — Faye et al., Gut 2023

Nationwide registry cohort — 6,104,245 Danish residents aged 10 and over, 2000–2018, 52,898 new cases of IBD. Moderate evidence. Gut 2023;72(4):663–670. DOI 10.1136/gutjnl-2022-327845. Free full text in PubMed Central (PMC9998355). Note: Observational: the infections being treated, rather than the antibiotics, may explain part of the link, and early undiagnosed IBD could prompt prescriptions.
What It Found
Following everyone in Denmark aged 10 or over from 2000 to 2018 (6.1 million people; 52,898 new cases of inflammatory bowel disease), antibiotic use was linked with a higher rate of IBD at every age: 28% higher at 10–40 years, 48% at 40–60 and 47% at 60 and over (incidence rate ratios 1.28, 1.48, 1.47). Risk rose with more courses, peaked 1–2 years after use, and was highest after antibiotics often used for gut infections.
Why It Matters Here
Explains how disturbing the gut microbiome may contribute to Crohn's disease and colitis, and why the authors see antibiotic stewardship as important; context for the IBD organisations and support groups in chapters 06 and 15.
Nationwide registry cohort — 6,104,245 Danish residents aged 10 and over, 2000–2018, 52,898 new cases of IBD. Moderate evidence. Gut 2023;72(4):663–670. DOI 10.1136/gutjnl-2022-327845. Free full text in PubMed Central (PMC9998355). Note: Observational: the infections being treated, rather than the antibiotics, may explain part of the link, and early undiagnosed IBD could prompt prescriptions.

Association of Infant Antibiotic Exposure With Childhood Health Outcomes — Aversa et al., Mayo Clin Proc 2021

Population-based birth cohort — 14,572 children born 2003–2011 in Olmsted County, Minnesota, followed to 2017. Moderate evidence. Mayo Clin Proc 2021;96(1):66–77. DOI 10.1016/j.mayocp.2020.07.019. Free full text in PubMed Central (PMC7796951). Note: Observational, from one US county; the infections antibiotics were given for may explain some links (confounding by indication), and reverse causation is possible.
What It Found
Of 14,572 children born in one US county, 70% had at least one antibiotic prescription before age 2. Early antibiotics were linked with higher risk of childhood asthma, allergic rhinitis, eczema (atopic dermatitis), coeliac disease, overweight, obesity and ADHD (hazard ratios 1.20 to 2.89). Links depended on the number, type and timing of courses. The authors stress their findings 'reflect associations, not causation'.
Why It Matters Here
Explains how antibiotics in the first two years, which disturb the developing gut microbiome, may be linked with later allergies, coeliac disease and weight; context for the coeliac organisations in chapter 15.
Population-based birth cohort — 14,572 children born 2003–2011 in Olmsted County, Minnesota, followed to 2017. Moderate evidence. Mayo Clin Proc 2021;96(1):66–77. DOI 10.1016/j.mayocp.2020.07.019. Free full text in PubMed Central (PMC7796951). Note: Observational, from one US county; the infections antibiotics were given for may explain some links (confounding by indication), and reverse causation is possible.

Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course — iMSMS Consortium, Cell 2022

Case–control study — 576 people with multiple sclerosis and 576 healthy household partners at seven sites in the USA, Argentina, Scotland and Spain. Early evidence. Cell 2022;185(19):3467–3486.e16. DOI 10.1016/j.cell.2022.08.021. Free full text in PubMed Central (PMC10143502). Note: A one-off comparison, so it cannot show whether microbes help cause MS or whether MS and its treatments change the microbes.
What It Found
Each of 576 people with multiple sclerosis was compared with a genetically unrelated healthy person from the same household (mostly spouses, sharing diet and surroundings). The MS group had more of some bacteria, such as Akkermansia muciniphila, and less of others, such as Faecalibacterium prausnitzii, a major butyrate producer; microbiome function also differed with MS treatments. The authors say the results 'strongly support' links with MS risk and course.
Why It Matters Here
Explains how the gut microbiome is being studied as an environmental factor in multiple sclerosis; context for the MS lifestyle programme in chapter 16 and the autoimmune communities in chapter 06, which this study did not test.
Case–control study — 576 people with multiple sclerosis and 576 healthy household partners at seven sites in the USA, Argentina, Scotland and Spain. Early evidence. Cell 2022;185(19):3467–3486.e16. DOI 10.1016/j.cell.2022.08.021. Free full text in PubMed Central (PMC10143502). Note: A one-off comparison, so it cannot show whether microbes help cause MS or whether MS and its treatments change the microbes.

Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer — Wirbel et al., Nat Med 2019

Meta-analysis of 8 case–control stool metagenome studies (N = 768) from 7 countries on 3 continents. Moderate evidence. Nat Med 2019;25(4):679–689. DOI 10.1038/s41591-019-0406-6. Free full text in PubMed Central (PMC7984229). Note: Case–control data cannot show whether the bacteria help cause cancer or the tumour changes the gut; the authors note causality is unresolved.
What It Found
Re-analysing eight stool-sequencing studies of colorectal cancer from seven countries, researchers found a core set of 29 bacterial species consistently enriched in people with the cancer, including Fusobacterium, Porphyromonas and Parvimonas. Cancer-linked microbiomes had more genes for breaking down protein and mucus and fewer for carbohydrates, which the authors say fits known dietary risks (red meat, low fibre). Signatures from one study kept their accuracy in the others.
Why It Matters Here
Explains how gut bacteria are linked with bowel cancer and why diet may be part of that link; context for the gut-health services and gastroenterologist finders in chapter 15.
Meta-analysis of 8 case–control stool metagenome studies (N = 768) from 7 countries on 3 continents. Moderate evidence. Nat Med 2019;25(4):679–689. DOI 10.1038/s41591-019-0406-6. Free full text in PubMed Central (PMC7984229). Note: Case–control data cannot show whether the bacteria help cause cancer or the tumour changes the gut; the authors note causality is unresolved.

Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis — Nikolova et al., JAMA Psychiatry 2021

Umbrella review and meta-analysis of 59 case–control studies across eight psychiatric disorders (diversity meta-analysis: 1,519 patients, 1,429 controls). Moderate evidence. JAMA Psychiatry 2021;78(12):1343–1354. DOI 10.1001/jamapsychiatry.2021.2573. Free full text in PubMed Central (PMC8444066) — open access, CC BY. Note: Case–control studies cannot show whether gut bacteria affect mental health or the illness, its medicines and diet change the bacteria; most studies were small to moderate in size.
What It Found
Across 59 case–control studies of depression, bipolar disorder, psychosis, anxiety, anorexia, OCD, PTSD and ADHD, patients overall had lower gut microbial richness (Chao1 standardised mean difference −0.5), consistently so only in bipolar disorder. Rather than disorder-specific patterns, they found a shared one: fewer anti-inflammatory, butyrate-producing bacteria (Faecalibacterium, Coprococcus) and more Eggerthella in depression, bipolar disorder, psychosis and anxiety.
Why It Matters Here
Explains what is known about gut bacteria in mental illness; background for the gut–brain research and information listings in chapter 15 and the food-and-mood course and books in chapter 10. The shared pattern means the microbiome is not a test for any one condition.
Umbrella review and meta-analysis of 59 case–control studies across eight psychiatric disorders (diversity meta-analysis: 1,519 patients, 1,429 controls). Moderate evidence. JAMA Psychiatry 2021;78(12):1343–1354. DOI 10.1001/jamapsychiatry.2021.2573. Free full text in PubMed Central (PMC8444066) — open access, CC BY. Note: Case–control studies cannot show whether gut bacteria affect mental health or the illness, its medicines and diet change the bacteria; most studies were small to moderate in size.

Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson's disease — Romano et al., Nat Commun 2025

Meta-analysis with machine learning — 22 case–control studies, 4,489 stool samples from 11 countries. Moderate evidence. Nat Commun 2025;16(1):4227. DOI 10.1038/s41467-025-56829-3. Free full text in PubMed Central (PMC12059030) — open access, CC BY 4.0. Note: Case–control data cannot show cause or effect; some differences may reflect Parkinson's medicines, and microbiome tests did not transfer well between studies.
What It Found
Pooling 4,489 stool samples from 22 case–control studies in 11 countries, the gut microbiome of people with Parkinson's disease differed consistently from that of controls, including fewer Faecalibacterium and more microbial genes for breaking down solvents and pesticides, which the authors relate to known environmental risk factors. Microbiome tests sorted patients from controls fairly well within a study (average AUC 71.9%) but poorly in other studies (61%).
Why It Matters Here
Explains what is and is not known about gut bacteria in Parkinson's disease; context for the Parkinson's organisations in chapter 06 and the gut–brain research centres in chapter 15.
Meta-analysis with machine learning — 22 case–control studies, 4,489 stool samples from 11 countries. Moderate evidence. Nat Commun 2025;16(1):4227. DOI 10.1038/s41467-025-56829-3. Free full text in PubMed Central (PMC12059030) — open access, CC BY 4.0. Note: Case–control data cannot show cause or effect; some differences may reflect Parkinson's medicines, and microbiome tests did not transfer well between studies.

Gut-microbiota-targeted diets modulate human immune status — Wastyk et al., Cell 2021

Randomised diet study — 18 healthy adults per arm, high-fermented-food vs high-fibre diet for 10 weeks within a 17-week study; no control arm. Early evidence. Cell 2021;184(16):4137–4153.e14. DOI 10.1016/j.cell.2021.06.019. Free full text in PubMed Central (PMC9020749). Note: Small study (18 healthy adults per diet) with no control group, a primary immune outcome that did not change, and no disease outcomes.
What It Found
Healthy adults were randomised to eat more fermented foods (such as yoghurt, kefir, kimchi and kombucha; up from 0.4 to 6.3 servings a day) or more fibre (21.5 to 45.1 g a day). In the fermented-food group, microbiome diversity rose steadily and 19 of 93 inflammatory proteins in the blood fell, including IL-6. The high-fibre diet did not raise diversity, and the main immune outcome did not change in either group.
Why It Matters Here
Backs up the fermentation book and food-and-mood resources in chapter 10 and ISAPP's fermented-food guidance in chapter 15 as a reason fermented foods are being studied; most relevant to people curious about yoghurt, kefir and kimchi.
Randomised diet study — 18 healthy adults per arm, high-fermented-food vs high-fibre diet for 10 weeks within a 17-week study; no control arm. Early evidence. Cell 2021;184(16):4137–4153.e14. DOI 10.1016/j.cell.2021.06.019. Free full text in PubMed Central (PMC9020749). Note: Small study (18 healthy adults per diet) with no control group, a primary immune outcome that did not change, and no disease outcomes.

Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries — Ghosh et al., Gut 2020

Microbiome sub-study of a 1-year randomised trial — 612 adults aged 65–79 in five European countries (323 Mediterranean-style diet, 289 controls). Early evidence. Gut 2020;69(7):1218–1228. DOI 10.1136/gutjnl-2019-319654. Free full text in PubMed Central (PMC7306987) — open access, CC BY-NC 4.0. Note: The links between microbiome changes and frailty were correlations within the trial, not randomised comparisons, so they do not show the bacteria caused the benefits.
What It Found
In 612 older adults in five European countries, a year of a Mediterranean-style diet tailored to older people (323 people, against 289 controls) did not change overall microbiome diversity, but closer adherence was linked with less loss of diversity and more of certain bacteria. Those diet-linked bacteria were associated with lower frailty, better cognitive function and lower inflammatory markers such as C-reactive protein.
Why It Matters Here
Backs up the Mediterranean-style cooking and eating-well resources in chapter 10 as one way to support the gut microbiome with age; most relevant to older adults and their carers.
Microbiome sub-study of a 1-year randomised trial — 612 adults aged 65–79 in five European countries (323 Mediterranean-style diet, 289 controls). Early evidence. Gut 2020;69(7):1218–1228. DOI 10.1136/gutjnl-2019-319654. Free full text in PubMed Central (PMC7306987) — open access, CC BY-NC 4.0. Note: The links between microbiome changes and frailty were correlations within the trial, not randomised comparisons, so they do not show the bacteria caused the benefits.

International consensus statement on microbiome testing in clinical practice — Porcari et al., Lancet Gastroenterol Hepatol 2025

International expert consensus (Delphi process) — 69 experts from 18 countries, 35 statements, each needing at least 80% agreement. Moderate evidence. Lancet Gastroenterol Hepatol 2025;10(2):154–167. DOI 10.1016/S2468-1253(24)00311-X. Free full text in PubMed Central (PMC12343204). Note: Expert consensus rather than trial evidence; it sets standards for good testing but cannot itself show which tests improve health.
What It Found
Sixty-nine microbiome experts from 18 countries agreed that there is not yet enough evidence to recommend routine gut microbiome testing in clinical practice. They discouraged people from ordering tests without a clinical recommendation and testing companies from giving treatment advice, and discouraged reporting the Firmicutes-to-Bacteroidetes ratio, finding too little evidence for any 'dysbiosis index'.
Why It Matters Here
Backs up the warnings about home gut-microbiome tests in chapter 15 (EUFIC explainer, NIST comparison of test services); most relevant to anyone thinking of paying for a stool microbiome test.
International expert consensus (Delphi process) — 69 experts from 18 countries, 35 statements, each needing at least 80% agreement. Moderate evidence. Lancet Gastroenterol Hepatol 2025;10(2):154–167. DOI 10.1016/S2468-1253(24)00311-X. Free full text in PubMed Central (PMC12343204). Note: Expert consensus rather than trial evidence; it sets standards for good testing but cannot itself show which tests improve health.

Treatment of periodontitis for glycaemic control in people with diabetes mellitus — Simpson et al., Cochrane Database Syst Rev 2022

Cochrane systematic review and meta-analysis — 35 randomised trials, 3,249 people with diabetes and gum disease. Strong evidence. Cochrane Database Syst Rev 2022;(4):CD004714. DOI 10.1002/14651858.CD004714.pub4. Free full text in PubMed Central (PMC9009294). Note: Only two trials were at low risk of bias, few followed people beyond six months, and most did not assess side effects.
What It Found
Thirty-five randomised trials (3,249 people, nearly all with type 2 diabetes) compared professional gum treatment, which removes plaque (the film of bacteria on teeth) and tartar from below the gumline, with no or usual care. Treatment lowered HbA1c by 0.43 percentage points (4.7 mmol/mol; 95% CI 0.28 to 0.59) at 3 to 4 months (30 trials, moderate-certainty evidence) and by 0.30 points at 6 months. Trials that checked for harms found none or only mild ones.
Why It Matters Here
Explains a link between gum disease, which is driven by the bacterial film on teeth, and blood-sugar control: treating it improved diabetes control in trials; relevant to people with diabetes using the metabolic-health resources in chapter 10.
Cochrane systematic review and meta-analysis — 35 randomised trials, 3,249 people with diabetes and gum disease. Strong evidence. Cochrane Database Syst Rev 2022;(4):CD004714. DOI 10.1002/14651858.CD004714.pub4. Free full text in PubMed Central (PMC9009294). Note: Only two trials were at low risk of bias, few followed people beyond six months, and most did not assess side effects.
Important Disclaimer
This directory is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your medication regimen or starting any new therapy.

This document does not guarantee the legitimacy, quality, or suitability of any business, organization, or practitioner listed within. The inclusion of any listing does not constitute an endorsement, recommendation, or verification of credentials. All organizations listed are independent entities over which the creators of this directory have no control or oversight.

This directory is intended to be used as a starting point and reference for the reader to conduct their own research, exercise their own judgment, and apply their own discretion before engaging with any listed organization or professional. Readers are strongly encouraged to independently verify credentials, read reviews, check licensing, and confirm current pricing and availability directly with each organization before committing to any services.

Costs, availability, contact details, and services may change at any time without notice. Information was accurate to the best of our knowledge at the time of publication.

About Notbroken.io: this directory and the accompanying Breathe, Calm, Sleep, Move, Eat, Track and Build tools were created by Nathan Leary, who runs and updates them. How each tool works, its safety notes, the privacy policy and terms of use are at notbroken.io/about, notbroken.io/privacy and notbroken.io/terms. The tools are general wellness aids, not medical devices, and Track is a personal journal that never gives medication advice.

If you are in crisis: Please contact your local emergency services immediately, or reach out to one of the following helplines:

International: Chapter 02 of this directory lists free helplines by situation and country; elsewhere use Find A Helpline — findahelpline.com
United States: 988 Suicide & Crisis Lifeline (call or text 988) • Crisis Text Line (text HOME to 741741)
United Kingdom: Samaritans — 116 123 (free, 24/7)
Canada: Talk Suicide Canada — 988 (call or text, 24/7)
Australia: Lifeline — 13 11 14 (24/7) • Beyond Blue — 1300 22 4636
New Zealand: Need to Talk? — 1737 (free, 24/7)
Europe: European Emergency Number — 112
India: iCall — 9152987821 • Vandrevala Foundation — 1860 2662 345
Singapore: Samaritans of Singapore — 1-767 (24/7)
Japan: TELL Lifeline — 03-5774-0992

No matches found

Nothing matched . Try broadening your search — remove a filter, use a single keyword, describe what you need in a sentence, or browse by a condition, a place, or a type of support.

Suggest a resource